Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

KMDA

+ Watchlist+ Portfolio

Kamada Ltd.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$8.16
52-Week Range
$6.60 – $9.35
Market Cap
$465.90M
P/E (TTM)
21.24
EPS (TTM)
0.38
Dividend Yield
2.11%
Advanced Metrics
Price/Book
1.72
PEG Ratio
0.65
Return on Equity
9.35%
Return on Assets
5.00%
Gross Margin
41.59%
Operating Margin
15.43%
Profit Margin
12.67%
Current Ratio
4.17
Debt/Equity
0.04
Total Debt
$11.72M
Free Cash Flow
$22.89M
Revenue Growth
10.70%
Earnings Growth
55.60%
Enterprise Value
$396.97M

Market Snapshot

About

Kamada Ltd. is an Israeli biopharmaceutical company specializing in plasma-derived protein therapeutics and biopharmaceutical products. The company develops, manufactures, and markets specialty pharmaceutical products with a focus on orphan indications and niche markets. Kamada's portfolio includes treatments for rare diseases such as hereditary angioedema, alpha-1 antitrypsin deficiency, and immunodeficiency disorders. The company operates its own plasma fractionation facility and partners with healthcare organizations globally to distribute its products.